Korro Bio, Inc. develops genetic medicines based on RNA editing for rare and highly prevalent diseases. The company uses its OPERA® oligonucleotide promoted editing of RNA platform to design therapies that harness endogenous RNA editing for precise, transient single-base edits.
Korro Bio news commonly covers corporate updates, financial results, scientific presentations, investor conference activity, and pipeline progress. Recurring program topics include KRRO-121 for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research for alpha-1 antitrypsin deficiency, private placement financings, equity-inducement grants, and other capital-structure and governance updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.